[Synergistic efficacy of adenovirus-mediated bcl-Xs gene therapy and cisplatin in ovarian cancer cell].
OBJECTIVE
To observe the presence of synergistic efficacy between adenovirus-mediated bcl-Xs (Adv-bcl-Xs) gene therapy and cisplatin (CDDP) in ovarian cancer cell.


METHODS
NuTu-19 cells were infected by different titers of Adv-bcl-Xs and treated with CDDP in the meantime. Percentage of cell proliferation was measured by methyl thiazolyl tetrazolium and cell cycles were measured by flow cytometry 3 days later. Graphical representations of the statistical analyses for their interaction in tumor cells.


RESULTS
The statistical results and Graphical representations of the statistical modeling showed that the synergistic antiproliferative activity was present (P < 0.01).


CONCLUSIONS
There was synergistic efficacy between Adv-bcl-Xs gene and CDDP for the inhibition of ovarian cancer cell.
Wang
H
H
Department of Obstetrics and Gynecology, Second University Hospital, West China University of Medical Sciences, Chengdu 610041, China.
Baker
V V
VV
D000260:Adenoviruses, Human / Q000235:genetics*; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology*; D005260:Female; D015316:Genetic Therapy / Q000379:methods; D010051:Ovarian Neoplasms / Q000473:pathology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D051381:Rats; D014162:Transfection; D014407:Tumor Cells, Cultured; D051020:bcl-X Protein
D000970:Antineoplastic Agents; C494813:Bcl2l1 protein, rat; D019253:Proto-Oncogene Proteins c-bcl-2; D051020:bcl-X Protein; D002945:Cisplatin